Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 2, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions

Mild Cognitive ImpairmentMild Alzheimer Disease

Interventions

DRUG

Nicotinamide riboside

Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.

Trial Locations (1)

RECRUITING

McLean Hospital, Belmont

All Listed Sponsors

collaborator

National Institute on Aging (NIA)

NIH

lead

Mclean Hospital

OTHER